Glavpolis® – MET 50/500

• Dipeptidyl peptidase-4 inhibitor; Reduces glycosylated haemoglobin (HbA1c)
• Improves β-cell function and glycemic control

METFORMIN

• First line agent for treatment of T2DM
• Inhibits gluconeogenesis through four different mechanisms

COMBINATION

• Potential to achieve better blood glucose control and improves compliance to therapy